Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | ANDROMEDA: daratumumab + CyBorD for AL amyloidosis

Efstathios Kastritis • 16 Jun 2020
EHA 2020
Amyloidosis Rare Diseases Antibodies Bortezomib Cyclophosphamide Daratumumab Dexamethasone
ANDROMEDA

Efstathios Kastritis, MD, of the University of Athens School of Medicine, Athens, Greece, discusses the Phase III ANDROMEDA study (NCT03201965) investigating subcutaneous daratumumab plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients with newly diagnosed amyloid light chain (AL) amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Efstathios Kastritis

1:45
Treatment options available for patients with AL amyloidosis beyond chemotherapy & transplant
Efstathios Kastritis • 27 Sep 2023
2:14
Managing renal failure in patients with multiple myeloma
Efstathios Kastritis • 27 Sep 2023
1:04
Treatment approaches for AL amyloidosis versus ATTR amyloidosis
Efstathios Kastritis • 27 Sep 2023
1:30
AL amyloidosis: current and prospective treatments
Efstathios Kastritis • 10 Jun 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals